Venclyxto®

Active substance venetoclax
Holder Abbvie
Status closed
Indication in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ineligible for intensive chemotherapy and who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious condition.
Public documents Approbation
  Information for the patient
  Informed consent
Last update

11/08/2022

Last updated on 13/02/2024